medigraphic.com
ISSN 0035-0052 (Print)

1998, Number 1

<< Back Next >>

Rev Mex Pediatr 1998; 65 (1)

Empleo de ambroxol en la terapia inicial del síndrome de dificultad respiratoria

Carbajal UJA, Pastrana HE

Language: Spanish
References: 26
Page: 15-18
PDF size: 124.09 Kb.


ABSTRACT

The utility of the ambroxol in the conventional treatment of neonates with of respiratory distress syndrome, was evaluated in two groups of newborns. The group «A» received ambroxol to 15 mg/kg/dose/12 h and the conventional treatment and the group «B» received exclusively the conventional treatment. The evolution evaluated by Silverman-Andersen, SpO2 and thorax radiographic.
The group «A» (n = 13) shown an improvement in the clinic and radiography findings, in the first 24 h, with increase of SpO2 (p = ‹ 0.05); the ventilatory attendance was of 14.3% and there was not fatalities. In the group «B» (n = 11) does not present differences in the clinical evolution and SpO2; the attendance ventilatory was done in 4 cases, all of them died.
In conclusion, ambroxol could be recommended in the conventional treatment of respiratory distress syndrome.


REFERENCES

  1. Yunes ZJ, Rodríguez AD y col. Enfermedad de membrana hialina. Bol Med Hosp Infant Mex 1993; 50(4): 284-292.

  2. García SJD. Síndrome de dificultad. En: Gómez M. Temas selectos sobre el recién nacido prematuro. México: Distribuidora y Editora Mexicana 1990; 215-223.

  3. Hallman M, Gluck L. Síndrome de insuficiencia respiratoria: Actualización 1982. Clin Pediatr Norteam 1982; 5: 1033-1051.

  4. Jobe A. Surfactante an the developing lung. En: Thibeault D, Gregory D. Neonatal pulmonary care. New York: Apleton-Century Crofts 1984; 75-99.

  5. Lerdo de Tejada A, López GR y col. Relación lecitina-esfingomielina, fósforo de lecitina fosfatidilglicerol en líquido amniótico. Correlación con el síndrome de insuficiencia respiratoria idiopática. Ginecol Obstet Mex 1981; 48: 365-372.

  6. Gluck L, Kulovich M et al. Diagnosis of the respiratory distress syndrome by amniocentesis. Am J Obstet Gynecl 1971; 109: 440-445.

  7. Gluck L, Kulovich M. Lecithin/Sphingomyelin ratios in amniotic fluid in normal and abnormal pregnancies. Am J Obstet Gynecl 1973; 115: 539-546.

  8. Jasso L. Neonatología práctica 3a. edición México: El Manual Moderno 1989; 267-270.

  9. Carbajal UJ, Pastrana HE. Incidencia del síndrome de dificultad respiratoria. Rev Med IMSS (Mex) 1996; 34(2): 169-172.

  10. Shapiro D, Nother F. Double randomized trial of calflung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 1985; 76: 593-599.

  11. Díaz del Castillo E. Pediatría perinatal. 3a. edición, México: Interamericana 1988; 224-230.

  12. Fujiwara T, Maeta H et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55-59.

  13. Honrning G, Shennan A et al. Prevention of neonatal respiratory distress syndrome by tracheal installation of surfactant: a randomized clinical trial. Pediatrics 1985; 76: 145-153.

  14. Raju TNK, Bhat R et al. Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hialine membrane disease. Lancet 1987; 1: 651-656.

  15. Lozano GC, Piña CV y col. Uso terapéutico del surfactante pulmonar en la enfermedad de membrana hialina neonatal. Bol Med Hosp Infant Mex 1993; 50: 481-491.

  16. Henrik VM, Bengt RMD et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994; 331: 1051-1055.

  17. Gil J, Thurnherr V. Morphometric evaluation of ultra-estructural changes in type 2 alveolar cells of rat lung produced by bromhexine. Respiration 1971; 28: 438-456.

  18. Hammer R, Bozler G, Jauch R, Koss FW. Speziesvergleich in pharmakokinetik und metabolismus von NA 872 Cl ambroxol bei ratten, kaninchen, hund und mensch Arzneimittel-Forschung. Drug Res 1978; (5a): 899-903.

  19. Löwenberg E, Jiménez L, Martínez M, Pommier M. Effects of ambroxol (NA 872) on biochemical fetal lung maturity and prevention of the respiratory distress syndrome. Prog Resp Res 1981; 15: 240-255.

  20. Kimya Y, Kucukkomurcus S, Ozan H, Uncu G. Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects. Clin Exp Obstet Gynecol 1995; 22(3): 204-211.

  21. Sackey S, Gadzinowski J, Szymankiewicz M, Breborowicz GH et al. Evaluation of ambroxol given prenatally and postnatally on gas exchange in the newborn with respiratory distress syndrome. Ginekol Pol 1995; 66(7): 409-412.

  22. Sackey S, Gadzinnowski J, Szymankiewicz M et al. Comparison of mortality an morbidity in newborns treated with ambroxol prenatally and postnatally. Ginekol Pol 1995; 66(8): 439-443.

  23. Lenclen R, Paupe A, Philippe HJ, Oliver-Martin M, Nisand I. Prenatal prevention of infant respiratory distress syndrome. 2nd part: Clinical applications and indications. J Gynecol Obstet Biol Reprod Paris: 1995; 24(3): 294-309.

  24. Wauer R, Schmalisch G et al. Randomized double blind trial of ambroxol for the treatment of respiratory distress syndrome. Eur J Pediatr 1992; 151: 357-363.

  25. Marini A, Franzetti M, Gios G et al. Ambroxol in the treatment of idiopathic respiratory distress syndrome. Respiration 1987; 51(1): 60-67.

  26. Ballesteros del Olmo JC, Reyes LF, Gracia OMR. Utilidad del ambroxol en el neonato con síndrome de dificultad respiratoria. Rev Mex Pediat 1994; 61(3): 120-125.




2020     |     www.medigraphic.com